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The interaction between tumor progression and innate immune system has been well established in the last years. Indeed, several
lines of clinical evidence indicate that immune cells such as tumor-associated macrophages (TAMs) interact with tumor cells,
favoring growth, angiogenesis, and metastasis of a variety of cancers. In most tumors, TAMs show properties of an alternative polar-
ization phenotype (M2) characterized by the expression of a series of chemokines, cytokines, and proteases that promote immuno-
suppression, tumor proliferation, and spreading of the cancer cells. Tumor suppressor genes have been traditionally linked to the
regulation of cancer progression; however, a growing body of evidence indicates that these genes also play essential roles in the
regulation of innate immunity pathways through molecular mechanisms that are still poorly understood. In this paper, we provide
an overview of the immunobiology of TAMs as well as what is known about tumor suppressors in the context of immune responses.
Recent advances regarding the role of the tumor suppressor ARF as a regulator of inflammation and macrophage polarization are
also reviewed.
1. Introduction
Immune system constitutes one of the first-line defenses to
prevent tumor development due to its ability to identify and
destroy tumor cells. This process defined as cancer immuno-
surveillance was initially described by Ehrlich and subse-
quently revisited by Thomas and Burnet [1–3], gaining con-
siderable attention in last years. Compelling evidence that
immune system modulates cancer has emerged over the last
decade from gene-targeted mice studies. Mice deficient in
several immune effector cells and molecules including inter-
feron (IFN)-γ receptor or signal transducer and activator of
transcription 1 (STAT1) [4], natural killer (NK) cells, NK-T
cells [5, 6], γδ T cells [7, 8], IL-12 [9], perforin [10], and
granulocyte-macrophage colony stimulating factor (GM-
CSF) [11] have been demonstrated to be more susceptible to
tumor development. Collectively, these studies strongly
support the concept that the immune response is essential in
the development of tumors.
2. Macrophages: Key Immune Cells
Macrophages are one of the major widely distributed innate
immune cells and present essential roles in the primary res-
ponse to pathogens, maintenance of tissue homeostasis, in-
flammation, and immunity.
Macrophages are derived from bone marrow progenitors
as immature monocytes. After circulating in the blood
stream, monocytes migrate into tissues where they differen-
tiate into resident macrophages [12].
Macrophages are dynamic cells that might modify their
functional profiles in response to a variety of stimuli polariz-
ing to functionally different phenotypes. Two distinct subsets


























Figure 1: Simplified scheme for M1 and M2 activation of macrophages. M1 macrophages are induced by LPS or IFN-γ secreting high
levels of classical proinflammatory cytokines such as TNF-α, IL-1, IL-6, IL-12, or IL-23, chemokines (e.g., Cxcl9, Cxcl10, and Cxcl5) and
increasing their concentrations of NO. In addition, they express high levels of MHC I. IL-4/IL-13 stimulation induces M2 macrophages
that downregulate IL-12 and IL-23 expression, release Ccl17, Ccl22 and Ccl24 chemokines and proangiogenic factors, and show increased
expression of IL-10. Additionally, they are characterized by expression of MR, Fizz-1, and Ym1.
of macrophages have been proposed, including classically
activated (M1) and alternatively activated (M2) macrophages
[13] (Figure 1). M1 macrophages are induced by IFN-γ
either alone or cooperating with microbial stimuli such as
lipopolysaccharide (LPS) or cytokines (e.g., tumor necrosis
factor (TNF)-α and GM-CSF). These cells secrete high levels
of classical proinflammatory cytokines such as TNF-α, inter-
leukin (IL)-1, IL-6, IL-12, or IL-23 and increase their concen-
trations of nitric oxide (NO), superoxide anions, and oxygen
radicals [14, 15]. Furthermore, M1 macrophages can express
high levels of major histocompatibility complex (MHC) I
and class II antigens and secrete complement factors that
facilitate complement-mediated phagocytosis [16].
In contrast, IL-4/IL-13 stimulation induces M2 macro-
phages that reduce IL-12 and IL-23 expression while upreg-
ulate the anti-inflammatory cytokine IL-10 [17, 18]. Addi-
tionally, they are characterized by the expression of the
scavenger receptors mannose receptor (MR) [13], stabilin-1
[19], CD163 [20], and some genes involved in tissue re-
modelling such as Found in Inflammatory Zone 1 (Fizz-1)
and chitinase 3-like 3 (Ym1) [21].
An alternative metabolic pathway of L-arginine, catalyzed
by arginase-1 (Arg-1) provides another feature of distinction
among the two macrophage activation states. M1 macro-
phages upregulate iNOS to catabolize L-arginine to NO and
citrulline, but M2 macrophages are characterized by high
expression of Arg-1, a cytosolic enzyme which metabolizes L-
arginine to ornithine and polyamines, which are precursors
for collagen synthesis and cellular proliferation [22].
M1 and M2 macrophages also express a different chemo-
kine repertoire. M1 macrophages produce proinflammatory
chemokines such as (C-X-C motif) ligand 9 (Cxcl9), Cxcl10,
and Cxcl5 [16], whereas M2 polarization is accompanied by
production of Ccl17, Ccl22, and Ccl24 [16].
This plethora of molecules and genes leads macrophages
to display distinct functions in virtue to their polarization
state. Thus, classically activated macrophages are vital com-
ponents in the initiation and maintenance of inflammation,
as well as in host defense and priming antitumor immune
response [13]. For instance, the IL-12 produced by M1
macrophages promotes the differentiation of naive T cells
into Th1 cells, stimulates growth of both T and NK cells, and
increases bactericidal activity of phagocytes. Moreover, IL-12
exerts an antiangiogenic activity through the increment of
the chemokine inducible protein-10 (IP-10 or Cxcl10) [23].
Additionally, M1 chemokines such as Cxcl9, Cxcl10, and
Cxcl5 induce the recruitment of Th1 cells, Tc1 cells, and NK
cells [16].
Opposite, M2 macrophages have poor antigen-present-
ing capability, produce factors that suppress T-cell prolifer-
ation and activity, and mainly participate in parasite clear-
ance, tissue remodeling, immune modulation, and tumor
progression [15]. Thus, IL-10 expressed by M2 macrophages
promotes the production of IL-4 and IL-13 by Th2 cells [24],
inhibits the synthesis of proinflammatory cytokines such as
IFN-γ, IL-2, IL-3, TNF-α and GM-CSF, and also suppresses
the antigen-presentation capacity of antigen presenting cells.
Furthermore, Ccl17, Ccl22, and Ccl24 production favors
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the attraction of immune-inhibitory cells such as regulatory
T-cells (Treg) [25].
3. Macrophages and Tumor Microenvironment
Compelling evidence has emerged in recent years for macro-
phages playing an important function in tumor develop-
ment. Although the role of macrophages in tumors is still
controversial, in most human cancers such as breast,
prostate, ovarian, cervical, lung carcinoma, and cutaneous
melanoma, a macrophage-rich microenvironment has been
correlated with a poor prognosis [26, 27]. These tumor-asso-
ciated macrophages (TAMs) share many common features
with the alternatively activated macrophages, showing a typi-
cal M2 marker profile with high expression of C-type lectin
receptors, stabilin-1, and Arg-1 [25].
Among the cell surface molecules expressed by TAMs,
several members of structurally related C-type lectin recep-
tors such as MR and Macrophage galactose-type C-type
lectin 1/2 (Mgl-1/2) are included [28]. The MR is an endo-
cytic and phagocytic receptor that was initially described as
a bridge between innate immunity and homeostasis [29] due
to its ability to bind carbohydrate moieties on several patho-
gens such as bacteria, fungi, parasites, and viruses. Mgl-1/2
are induced on macrophages by parasitic infections or aller-
gic asthma [28]. In the tumor microenvironment, MR and
Mgl-1/2 have been documented to act as recognition mole-
cules for glycosylated antigens on cancer cells. MR and Mgl-
1/2 recognize specifically highly glycosylated molecules such
as mucins present in the tumor microenvironment [30],
leading to the expression of the immunoregulatory cytokine
IL-10 that favors the attraction of Treg cells [25]. Indeed,
Mgl-1/2 is predominantly expressed by TAMs from human
ovarian carcinoma [31], on lung metastasis produced by
mouse metastatic ovarian tumor cells [32], and also they
have been detected after challenging tumor conditioned
medium [33].
Chitinase 3-like 3 (Ym1) is a member of the mammalian
chitinase family that also includes Ym2 and BRP-39 in mice,
and YKL-40 in humans [34]. Increased expression of these
proteins has been associated with inflammatory diseases, in
particular with allergic asthma, with the induction of alter-
native activation of macrophages, and with progression of
cancer [35–39].
Fizz-1, also known as resistin-like molecule α (RELM-α),
plays a key role in the regulation of cell growth/proliferation
and differentiation. Initially described in lung allergic in-
flammation [40], it is highly expressed in bleomycin-induced
lung fibrosis and after IL-4 or IL-13 activation [41, 42]. Fizz-
1 exhibits multiple functions including cell proliferation,
angiogenesis, and inflammation [43], and its expression is an
indicator of M2 polarization [21, 39].
Stabilin-1, a type-1 transmembrane receptor that medi-
ates clearance of “unwanted self” components, is another
marker for M2 macrophages that has been found to be ex-
pressed by TAM in several murine tumor models (e.g., B16
melanoma, pancreatic insulinoma, breast carcinoma) [19,
44]. Stabilin-1 mediates internalization of extracellular
secreted protein acidic and rich in cysteine (SPARC), regu-
lating its concentration and thereby promoting extracellular
matrix remodeling, angiogenesis, and tumor progression
[45].
4. Role of TAMs in Tumors
TAMs derive from circulating monocytic precursors pre-
viously recruited to the tumor region in response to the
chemokines and cytokines secreted by cancer cells. In the
tumor mass, TAMs exert immunosuppressive functions
through the release of anti-inflammatory cytokines, mod-
ulate the tumor microenvironment producing survival/
growth factors (e.g., vascular endothelial growth factor,
VEGF), and facilitate the progression of tumors via proan-
giogenic factors release [25, 26].
4.1. TAMs and Immunosuppression. A relevant function of
TAMs is to diminish the effective antitumor immune res-
ponse. Several cytokines and proteases derived from TAMs,
such as transforming growth factor (TGF)-β, IL-10 and Arg-
1, make a significant contribution to the immunosuppressive
condition [46–48].
TGF-β inhibits the antitumor response through different
mechanisms including (i) inhibition of the cytolytic activity
of NK cells [48, 49], (ii) differentiation of CD4+ T cells into
Th2 cells [50], (iii) inhibition of the CD8+ T cells antitumoral
activity [48], and (iv) maintenance of Treg cell differentiation
[48].
IL-10 promotes the immune evasion impeding the pro-
duction of IL-12, a cytokine known to stimulate both the
proliferation and cytotoxicity of T and NK cells [51], as well
as the release of the cytokine IFN-γ, which is the main factor
that stimulates naive T-cell differentiation [52]. Additionally,
it has been reported that IL-10 decreases the ability of epi-
dermal antigen presenting cells (APCs) to present tumor-
associated antigens, therefore interfering the induction of
antitumor immune responses [51].
High Arg-1 activity has been described in TAMs from
3LL murine lung carcinoma [22], human papillomavirus
E6/E7-expressing murine tumors [53], and CD11b+/CD14−
myeloid cells from renal carcinoma patients [54]. Elevated
Arg-1 expression might promote tumor growth via several
mechanisms including downregulation of NO-mediated
tumor cytotoxicity [55], increasing cellular proliferation
through its participation in polyamine and proline synthesis,
dysregulating the T cell receptor (TCR) signaling and sub-
sequently inducing CD8+ T cell unresponsiveness [47] and
enhancing the capacity of myeloid suppressor cells to inhibit
T cell proliferation [22].
Finally, TAMs release chemokines that play fundamental
roles in immunosuppression. Ccl13, Ccl18 (human only),
Ccl22, and to a lesser extent Ccl17 are important chemoat-
tractant for immune-inhibitory cells, such as Treg, which
might inhibit antitumor immunity resulting in tumor
growth and decreased patient survival [16]. Moreover, Ccl2
and Ccl5 suppress the T-cell responses [16].
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4.2. TAMs and Angiogenesis. Accumulating evidence indi-
cates that TAMs exert a critical function in regulating angio-
genesis, the process by which new blood vessels sprout from
the existing vasculature. TAMs depletion studies in mice
showed reduction of blood vessel density in the tumor tissue
[56] and numerous correlations between increased TAM
numbers and high vascular grades have been reported for
many tumor types [57–62].
TAMs support tumor cell invasion by secreting a broad
repertoire of molecules, including growth factors, cytokines,
proteases, and chemokines. For instance, TAMs release
potent proangiogenic cytokines such as IL-8 (or Cxcl8) and
growth factors as vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), and TGF-β, which
have been reported to promote angiogenesis in tumors such
as gliomas, squamous cell carcinomas of the esophagus, and
breast, bladder, and prostate carcinomas [59–63]. Impor-
tantly, they also release chemokines like Ccl2, Ccl5, Cxcl9,
and Cxcl16 that contribute to angiogenesis [64]. Moreover,
TAM-derived proteases, such as matrix metalloproteases
(MMP-1, MMP-2, MMP-3, MMP-9, and MMP-12) are also
beneficial to angiogenesis [65–67].
Additionally, TAMs have been found to accumulate in
hypoxic regions of human and experimental tumors (includ-
ing human endometrial, breast, prostate, and ovarian carci-
nomas) [68]. TAMs respond to the hypoxic microenviron-
ment by upregulating the hypoxia-inducible transcription
factors HIF-1 and HIF-2 that induce the expression of pro-
angiogenic genes, such as VEGF, Cxcl8, and Cxcl12.
4.3. TAMs and Tumor Growth. Macrophage depletion
studies have proven that TAMs are essential for tumor
growth [69] and TAMs infiltration has been observed in
several tumors such as breast cancer, endometrial cancer, and
renal cell cancer [70], demonstrating a positive correlation
between proliferation of tumor cells and TAMs infiltration.
Several molecules/factors secreted by TAMs such as MMP-
9, IL-23, IL-10 facilitate tumor cell proliferation thereby
limiting the cytotoxicity of the microenvironment.
4.4. TAMs and Metastasis. Another process in which TAMs
have been involved is in the regulation of metastasis. Indeed,
a correspondence between the number of macrophages in
metastatic sites and the metastatic potential of the tumor has
been observed [71], and systemic depletion of macrophages
results in reduced formation of lung metastases [72]. These
findings are in line with clinical studies showing that
increased numbers of macrophages in regional lymph node
metastases correlates with poor patient survival [73].
TAMs appear to influence the microenvironment to faci-
litate migration of tumor cells [74, 75] by the release of
MMPs, for example, MMP-2, MMP-7, and MMP-9. Those
MMPs contribute to transform the proteins of the extracel-
lular matrix and induce the expression of lymphatic endothe-
lial growth factor (VEGF-C), events that promote dissemina-
tion of tumor cells by stimulating the formation of lymphatic
vessels in tumors [76].
5. Tumor Suppressors and Immune System
Tumor suppressor genes act as sensors of multiple forms
of cellular stress, being regulated to induce cell-cycle arrest,
senescence, or apoptosis. Nevertheless, in last decades, a
growing body of evidence indicates that tumor suppressors
play a key role in the modulation of innate immune system,
a function more relevant even than their activity as cancer
inhibitors.
For instance, innate immune response in the metazoan
Caenorhabditis elegans has been described to be dependent
on p53 function [77]. A clear function in antiviral defense
has been reported for the tumor suppressors p53, the pro-
myelocytic leukemia (PML) protein, and the alternative
reading frame (ARF) [78–82]. Activation of PML, p53, and
ARF has been described after IFN treatment, expression of
viral proteins and viral infection [79, 82–87].
In addition, a molecular link between p53, ARF, retino-
blastoma protein (Rb), and Toll-like receptors (TLRs) has
been shown [87–89] and recent studies have demonstrated
that ARF regulates inflammatory response [87].
5.1. The Retinoblastoma Protein Rb. Rb was identified as the
protein responsible for the congenital tumor retinoblastoma
[90] and plays pivotal roles in cell cycle control, differen-
tiation, and inhibition of oncogenic transformation. Rb
regulates cellular proliferation by directly binding to E2F
transcription factors [91, 92], a family of transcription
factors that regulates cellular proliferation, growth, and dif-
ferentiation.
Furthermore, additional functions of Rb in the control
of immune response have been described including a novel
role in viral infection surveillance. Thus Rb is required for the
activation of the NF-κB pathway in response to virus infec-
tion [93]. In addition, a recent report has shown that Rb pos-
itively regulates expression of TLR3, the sensing receptor for
viral double-stranded RNA [89]. The mechanism involves
modulation of the transcription factor E2F1, which directly
binds to the proximal promoter of TLR3.
5.2. The Promyelocytic Leukemia (PML) Protein. The PML
gene was originally identified in acute promyelocytic
leukemia (APL), being implicated in numerous cellular func-
tions including oncogenesis, DNA damage, senescence,
apoptosis, and protein degradation. In addition, accumulat-
ing reports have also demonstrated the role of PML in host
antiviral defense [78]. PML functions as the organizer of
PML nuclear bodies (NBs) that contains some proteins
recruited in a transient manner and two permanent NB-asso-
ciated proteins, the IFN-stimulated gene product Speckled
protein of 100 kDa (Sp100) and death-associated dead pro-
tein (Daxx) [94]. PML is induced by IFN leading to a marked
increase in the expression of several PML isoforms (PMLI-
PMLVII) and NBs. PML confers resistance to numerous
virus including foamy virus (HFV), vesicular stomatitis virus
(VSV), influenza virus, poliovirus, rabies virus, lymphocytic
choriomeningitis virus (LCMV), and encephalomyocarditis
virus [78, 95–99]. Interestingly, viruses inhibited by PML
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have developed various strategies to counteract the antiviral
defense mechanisms by altering PML expression and/or
localization on nuclear bodies [100].
5.3. Tumor Suppressor p53. The tumor suppressor p53 also
known as “the guardian of genome” is activated in response
to several types of cellular stress, including DNA damage
and oncogene expression. Under normal conditions, p53 is
maintained at very low levels through regulation by murine
double minute 2 (Mdm2) protein. Mdm2 inhibits p53 trans-
activation and prompts p53 for proteasomal degradation by
promoting its ubiquitination [101, 102]. However, in res-
ponse to cellular stress, such as DNA damage, heat shock, or
hypoxia, p53 levels rise as a consequence of activation of the
tumor suppressor ARF that binds to Mdm2 and inhibit the
ubiquitination, nuclear export, and subsequent degradation
of p53 [103].
p53 has been implicated in multiple functions that
play key roles in health and disease, including ribosome
biogenesis, control of aging, cell cycle arrest, and apoptosis,
having a clear importance in tumor suppression [104].
Interestingly, several lines of evidence also indicate that p53
may have a broader function in antiviral defense. Activation
of p53 by IFN has been reported [80, 81] and p53-deficient
mice are more permissive to viral infection [82]. This p53-
mediated protection against viral infection is related with
an induction of apoptosis, which is associated with reduced
viral replication [82]. Moreover, in addition to activation of
p53 by IFN, several genes involved in innate immunity have
been described to be p53 direct transcriptional targets. IFN
regulatory factors (IRFs) such as IRF-9 and IRF-5 have been
described to be modulated by p53 [80]. Several mechanisms
have been proposed for regulation of IRF-9 by p53 including
upregulation at the transcriptional level [80], transactivation
in response to influenza virus infection [105], and direct
p53-IRF9 protein interaction upon Hepatitis C virus (HCV)
infection [106]. Regarding IRF-5, an increase in IRF-5 levels
in cancer cell lines has been shown through p53 binding and
transactivation of the IRF-5 promoter [107].
Pattern recognition receptors such as TLR3 have also
been reported to be regulated by p53 [88]. TLR3 plays a
major role in the recognition of virus infection leading to
the induction of the IFN pathway [108]. p53 activates TLR3
transcription by binding to the p53 consensus site in the
TLR3 promoter. Moreover, TLR3 expression was downreg-
ulated in liver and intestine of p53−/− mice and HCT116
p53−/− cells, leading to a dysfunction in both NF-κB and IRF-
3 signaling pathways [88]. Upregulation of TLR3 activity by
p53 may also be responsible for the activation of interferon-
stimulated gene 15 (ISG15). ISG15 is strongly induced by
type I interferons and displays antiviral activity. Although a
functional p53 binding site adjacent to the core ISRE site of
ISG15 has been reported, upregulation of ISG15 has been
observed after dsRNA stimulation rather than in response
to IFN treatment or virus infection, suggesting that the
observed effects on ISG15 could be mediated through p53-
dependent upregulation of TLR3 activity [109].
Finally, important proinflammatory chemokines such as
monocyte-chemoattractant protein (MCP)-1 have also been
reported to be transcriptionally regulated by p53 [110].
MCP-1, also known as Ccl2, triggers the infiltration and
activation of cells of the monocyte-macrophage lineage and
has been linked with antitumor immunity [111] and cervical
cancer [112].
Thus, in addition to the well-established function of p53
as a tumor suppressor through regulation of apoptosis or cell
cycle, p53 exerts essential roles in the expression of key
molecules of the innate immune response. Indeed, the loss of
p53 function during carcinogenesis might affect the recogni-
tion of tumor cells by the immune system through interfering
with inflammatory mediators expression.
5.4. The Tumor Suppressor ARF. Tumor suppressor ARF
(p14ARF in human, p19ARF in mouse) is among the most
frequent genes mutated in human cancer [113]. ARF is
encoded by the INK4a/ARF locus (Cdkn2a) that generates
two unrelated proteins, the cyclin-dependent kinase inhibi-
tor p16INK4a and ARF, which, respectively, regulate the
activity of Rb and the p53 transcription factor [114, 115].
ARF activates p53 by sequestering Mdm2, an E3 ubiquitin
ligase, to the nucleolus, thereby inhibiting the Mdm2-
mediated proteasomal degradation of p53. p53 subsequently
activates p21 (CIP1/WAF1), which inhibits the cell cycle
[103, 116]. Although tumor suppressor activity of ARF was
initially attributed to p53 regulation, several p53-indepen-
dent actions for ARF have been described [117]. Thus, ARF
inhibits ribosomal RNA processing [118] and transcriptional
factors that induce proliferation such as E2F1, Myc, and
Forkhead box M1 (Foxm1b) [119–121]. In addition, ARF
interacts with the protein related with cell proliferation
nucleophosmin (NPM) [122].
Recent studies have shown that the tumor suppressor
ARF is more than a simple tumor suppressor and acts a
general sensor for different situation of cellular stress. In this
context, a regulatory network between Heat shock protein 70
(Hsp70), ARF, and β-catenin has been shown after oxidative
stress that leads to the induction of apoptosis [123]. ARF
deficiency has been reported to aggravate atherosclerosis
through the reduction of macrophage and vascular smooth
muscle cell apoptosis [124]. ARF is also expressed transiently
during mouse male germ cell and eye development and
its inactivation compromises spermatogenesis as mice age
and leads to aberrant postnatal proliferation of cells in the
vitreous of the eye, resulting in blindness [125].
Furthermore, ARF plays an important role in the
regulation of innate immunity and inflammatory processes.
Several reports have described an antiviral action of ARF as
well as its activation after the expression of viral proteins,
viral infection, or type I IFN treatment [79, 85–87]. Indeed,
the analysis of the ARF promoter revealed the presence of
IFN response elements such as IRF-3 and interferon-sensitive
response element (ISRE). The protective effect of ARF
against viral infection seems to be a general feature for
IFN-sensitive viruses as demonstrated the studies using VSV
and Sindbis virus or vaccinia virus (VV) [79]. Mechanism
involved in this protection is due, at least in part, to
interaction with NPM and activation of the double-stranded
RNA-dependent protein kinase, PKR [79].












































































Figure 2: Alternative activation in ARF-deficient macrophages. In WT macrophages, a balance between M1 and M2 phenotype is established,
depending on stimuli. Inflammatory stimuli induce NF-κB signaling pathways through the phosphorylation and subsequent ubiquitin-
dependent degradation of IκBα by the 26S proteasome. Then, NF-κB translocates to the nucleus inducing target gene expression. ARF present
in the nucleus displays physical and functional interaction with E2F1 resulting in destabilization of E2F1 protein and activation of NF-κB.
However, ARF-deficient macrophages establish an immunosuppressive and tolerant microenvironment via impairment of M1 signals. When
NF-κB translocates to the nucleus, excessive E2F1 inhibits NF-κB by binding to its subunit p65 in competition with the heterodimeric partner
p50. Moreover, excessive E2F1 may inhibit transcriptional expression of TLRs. This leads to secretion of M2 chemokines Ccl17 and Ccl22,
release of the anti-inflammatory cytokine IL-10, and stimulation of angiogenesis through expression of VEGF and MMP-9.
Interestingly, it has been recently described that ARF is a
critical modulator of the inflammatory response and macro-
phage activation. It has also been reported a molecular link
between ARF and TLRs [87]. Additionally, a manuscript by
Herranz et al. [126] suggests that ARF might modulate the
M1/M2 polarization and functional plasticity of macro-
phages (Figure 2).
Mice lacking the ARF gene are resistant to LPS-endotoxic
shock, and a significant reduction of leukocyte recruitment
in a model of thioglicollate-induced peritonitis was also
reported [87]. Moreover, ARF-deficient macrophages pre-
sent an impaired ability to develop proinflammatory pro-
perties showing a relevant downregulation of genes involved
in M1 macrophage phenotype and inhibition of the anti-
microbial and antitumoral responses, including expression
of proinflammatory cytokines (TNF-α, IL-1β), chemokines
(Cxcl10, Cxcl1, Ccl4), and inflammatory mediators (iNOS/
PGE2). Mechanisms involved in this inhibitory effect have
not been fully explored, although a decrease in NF-κB and
Mitogen-activated protein kinases (MAPK) activation have
been described in ARF−/− macrophages after stimulation
with LPS [87], as well as inhibition of IκB degradation in
ARF-deficient macrophages stimulated with VSV [79]. Fur-
thermore, an increase of the transcription factor E2F1 at
basal state and after LPS-stimulation has been shown in
absence of ARF [87]. E2F1 has been proposed to be an anti-
inflammatory and immunosuppressive transcription factor
since it represses NF-κB-dependent inflammatory signaling
[127, 128]. Therefore, it has been proposed that in normal
cells, ARF interacts with E2F1, resulting in destabilization
of E2F1 protein and activation of NF-κB. In contrast, in the
absence of ARF, E2F1 is overexpressed, and although NF-κB
translocates to the nucleus, excessive E2F1 inhibits its activity
by binding to p65 and thereby suppressing NF-κB-dependent
genes (iNOS, COX-2, chemokines, etc.).
Loss of ARF gene can abrogate tumor surveillance
mechanisms and increase cancer susceptibility. Indeed, mice
lacking p19ARF are highly prone to tumor development
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[129, 130] and deletion of ARF has been described in a
variety of malignancies, including glioblastoma, melanoma,
pancreatic adenocarcinoma, and non-small-cell lung cancer.
Interestingly, M2-polarized TAMs have been demonstrated
to be associated with poor prognosis and progression in
many of these tumors.
However, the link between ARF and immune response in
the tumoral context remains an open question. A manuscript
by Herranz et al. [126] goes deep into the immune role
of ARF, evaluating its possible contribution to the M1/M2
polarization of macrophages. In this study, authors demon-
strate that ARF deficiency switches macrophages to a M2-
like phenotype. Thus, in addition to downregulation of
proinflammatory mediators, typical hallmarks of an anti-
inflammatory M2-activation state were increased in both
resting and IL-4-treated ARF−/− macrophages, as exempli-
fied by the upregulation of Arg-1, Fizz-1 and Ym1. Moreover,
the cytokine/chemokine pattern induced by IL-4 stimula-
tion appeared upregulated in macrophages isolated from
ARF−/− mice showing an M2-phenotype with higher levels
of IL-10, Ccl22, Ccl5, Ccr3, or Ccr5. Together with these
M2 markers, important proangiogenic factors such as VEGF
and MMP-9 were also increased, suggesting the potential
protumoral action of ARF−/−macrophages. Consistent with
this notion, recent studies have demonstrated a role for
ARF in suppressing tumor angiogenesis via modulation of
VEGF expression [131] and the activity of its transactivator
HIF [132]. Notably, ARF has also been described to inhibit
angiogenesis by up-regulating the expression of TIMP3, an
inhibitor of MMPs activity [133].
Taken together, it is tempting to speculate that ARF has a
profound influence in regulating the polarization of macro-
phages. Thus, ARF deficiency might modify the immune
tumor microenvironment as a result of the induction of mul-
tiple activities including (a) immune suppression, through
the production of the anti-inflammatory cytokine IL-10 and
the secretion of Ccl22 and Ccl2 that attracts Tregs, (b)
stimulation of angiogenesis through expression of VEGF and
MMP-9, and (c) induction of matrix remodeling through the
production of MMP-9, Fizz-1, and Ym1.
6. Conclusions
More and more evidence indicates that tumor suppressors
play an essential role in host immunity, placing them as
general sensors and modulators of innate immune response.
Mechanisms involved in this process remain unclear,
although transcriptional regulation of several inflammatory
mediators has been reported. In addition, M1/M2 polar-
ization and functional plasticity of macrophages have been
shown to be modulated by tumor suppressors. These studies
reveal positive effects of tumor suppressors on cancer im-
munosurveillance that will pave the way for new targeted
therapies.
Therefore, identification of the role of tumor suppressors
in the pathways responsible for the skewing of macrophage
function as well as in the regulation of inflammatory
mediators will remain an important area of investigation in
the years to come.
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